Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
STELLAR-NP
- Development stage
- Unknown
- Lead developer
- Vaxinano
- Modality
- Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intranasal
01
Overview
STELLAR-NP is a proprietary nanoparticle vaccine delivery platform developed by Vaxinano. The technology is designed to present inactivated whole-pathogen antigens to the immune system, thereby enhancing the immunogenicity of vaccine candidates without the need for traditional chemical adjuvants. This platform is versatile, supporting the development of vaccines for a wide range of infectious diseases in both human and veterinary medicine. Currently, the platform is being applied to several programs in preclinical and early clinical (Phase 1) development, aiming to provide a safe and effective delivery mechanism for complex antigens.
Beyond the preview
Go deeper on STELLAR-NP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on STELLAR-NP.